Indaptus Therapeutics Q3 EPS $(0.47) Beats $(0.55) Estimate
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics reported Q3 losses of $(0.47) per share, beating the analyst consensus estimate of $(0.55) by 14.55 percent. However, this is a 11.9 percent increase in losses compared to the same period last year.
November 06, 2023 | 10:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Indaptus Therapeutics reported better than expected Q3 losses, but the losses increased compared to last year.
While Indaptus Therapeutics beat the Q3 EPS estimate, the increase in losses compared to the same period last year could potentially offset any positive sentiment. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100